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DOT1L safeguards cartilage homeostasis
and protects against osteoarthritis
Silvia Monteagudo1, Frederique M.F. Cornelis1, Carolina Aznar-Lopez1, Ploi Yibmantasiri1, Laura-An Guns1,
Peter Carmeliet2,3, Fre´de´ric Cailotto1,4 & Rik J. Lories1,5
Osteoarthritis is the most prevalent and crippling joint disease, and lacks curative treatment,
as the underlying molecular basis is unclear. Here, we show that DOT1L, an enzyme involved
in histone methylation, is a master protector of cartilage health. Loss of DOT1L disrupts the
molecular signature of healthy chondrocytes in vitro and causes osteoarthritis in mice.
Mechanistically, the protective function of DOT1L is attributable to inhibition of Wnt
signalling, a pathway that when hyper-activated can lead to joint disease. Unexpectedly,
DOT1L suppresses Wnt signalling by inhibiting the activity of sirtuin-1 (SIRT1), an important
regulator of gene transcription. Inhibition of SIRT1 protects against osteoarthritis triggered by
loss of DOT1L activity. Modulating the DOT1L network might therefore be a therapeutic
approach to protect the cartilage against osteoarthritis.
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A
rticular cartilage is an essential component of our joints
and critical for normal mobility. This cartilage contains a
unique cell-type, the articular chondrocyte, which is
embedded in self-produced extracellular matrix composed
mainly of type 2 collagen ﬁbres and proteoglycan aggrecan.
Osteoarthritis, the most common joint disease, is characterized by
progressive damage to the articular cartilage. In osteoarthritis, the
chondrocytes die or lose their highly specialized molecular
characteristics, resulting in the production of an extracellular
matrix that is biomechanically inferior, contributing to
progressive tissue damage and loss of joint function1. Thus, this
age-related or trauma-triggered progressive disease poses a
medical health threat and debilitates affected patients. Current
therapy is limited to symptom relief and in severe cases joint
replacement surgery; interventions that arrest or reverse disease
progression are entirely lacking and therefore indicate a large
unmet medical need2. Effective anti-osteoarthritic drugs should
maintain cartilage homeostasis and structural integrity, but the
central molecular regulators of these processes are unknown,
precluding the development of effective, safe treatments.
The Disruptor of telomeric silencing 1-like (DOT1L) gene
encodes a histone methyltransferase that methylates lysine-79 of
histone H3 (H3K79) and is involved in epigenetic regulation of
gene transcription3–5. Genome-wide association studies showed
that common single variants in the DOT1L gene, with minor
allele frequencies of 0.20–0.40, protect against osteoarthritis6,7.
However, it is unknown how DOT1L affects this devastating
disease.
In this study, we identify DOT1L as a regulator of cartilage
health and disease. Loss of DOT1L disrupts cartilage homeostasis
and triggers the development of osteoarthritis. Furthermore,
DOT1L preserves cartilage health by preventing the
hyper-activation of Wnt signalling through negative regulation
of SIRT1. Overall, our data demonstrate the importance of the
DOT1L/SIRT1 axis in maintaining cartilage health and provides a
rationale for potential therapeutic interventions in the treatment
of osteoarthritis.
Results
Loss of DOT1L activity disrupts chondrocyte homeostasis.
To study whether cartilage degeneration in osteoarthritis is
related to changes in DOT1L activity, we performed
immunohistochemistry of DOT1L-methylated H3K79 on
cartilage from non-osteoarthritic trauma patients and on
preserved and damaged regions of cartilage from patients with
osteoarthritis (Fig. 1a). This analysis revealed that the
immunoreactive signal of methylated H3K79 was decreased i‘n
damaged areas from patients with osteoarthritis as compared to
their corresponding preserved areas and to control cartilage. In
contrast, DOT1L gene expression did not differ between damaged
or preserved cartilage from patients with osteoarthritis (average
fold change in damaged versus preserved cartilage 0.992
(s.e.m. 0.064), n¼ 4 patients, with three technical replicates).
These observations suggest that DOT1L activity positively
correlates with cartilage health.
We next sought to determine if DOT1L regulates transcrip-
tional programs that maintain the unique molecular signature of
the articular chondrocyte. To address this question, we used an
in vitro model in which freshly isolated healthy human articular
chondrocytes are cultured and serially passaged in monolayer,
thereby losing their molecular characteristics, as it occurs in
osteoarthritis8. In this osteoarthritis-like dedifferentiation
process, the expression of chondrocyte markers such as type 2
collagen (COL2A1) and aggrecan (ACAN) is lost, while ﬁbroblast
markers such as type 1 collagen (COL1A1) are upregulated9. We
examined how DOT1L inhibition affects gene expression changes
triggered in this model. When the articular chondrocytes were
expanded and passaged while treated with the speciﬁc DOT1L
inhibitor EPZ-5676, H3K79 methylation was successfully
abrogated (Supplementary Fig. 1a,b). DOT1L inhibition
enhanced the osteoarthritis-like gene expression changes, for
example, augmenting loss of COL2A1 and gain of COL1A1
expression (Fig. 1b). These results suggest that the
methyltransferase plays a role in maintaining the molecular
identity of the healthy articular chondrocyte.
In vivo loss of DOT1L activity triggers osteoarthritis. We
then studied whether loss of DOT1L activity in vivo triggers
osteoarthritis, by intra-articular injection of EPZ-5676 into the
knees of adult mice. H3K79 methylation was effectively inhibited
by EPZ-5676 in articular chondrocytes (Fig. 1c). We observed
increased cartilage damage by histology 2 and 4 weeks after
EPZ-5676 injections (Fig. 1d,e). There were no differences
between the groups in severity of synovitis or extent of
subchondral bone remodelling, tissues that are known to show
other features of osteoarthritis10 (Supplementary Fig. 2). Thus,
these data suggest that DOT1L preserves articular cartilage
homeostasis, protecting it against osteoarthritis.
DOT1L limits Wnt signalling to maintain cartilage homeostasis.
To understand the mechanism by which DOT1L controls cartilage
homeostasis and to identify effector signalling pathways, we per-
formed genome-wide transcriptome analysis in healthy human
articular chondrocytes treated with EPZ-5676 or vehicle (geonr:
GSE77916). Microarray results and subsequent qPCR validation
conﬁrmed the induction of osteoarthritis-like gene expression
changes upon DOT1L blockade (Supplementary Fig. 3a
and Supplementary Table 1). Comparative pathway analyses of
differentially regulated transcripts after EPZ-5676 treatment
revealed an enrichment in genes associated with Wnt signalling
(Fig. 2a). Additional analyses highlighted the diverse regulatory role
of DOT1L and further supported the links with skeletal biology and
disease (Supplementary Fig. 3b,c).
Tight regulation of Wnt signalling is key to cartilage health as
both insufﬁcient and excessive high levels have been associated
with osteoarthritis11–13. Upon Wnt ligand binding to Fizzled
receptors and co-receptors including low-density lipoprotein
receptor-related protein (LRP) 5/6, b-catenin is rescued from
proteasomal degradation, accumulates in the cytoplasm and
translocates into the nucleus, where it associates with
transcription factors from the TCF/LEF family.
Immunoprecipitation analysis demonstrated that DOT1L
interacts with b-catenin, the key signalling molecule in the Wnt
cascade (Fig. 2b).
To ﬁnd out how DOT1L affects Wnt signalling, we determined
the effects of DOT1L inhibition on the activation of this pathway
in healthy human articular chondrocytes and in mouse models.
In Wnt reporter-transfected cells, EPZ-5676 increased the
luciferase activity when the Wnt signalling pathway was activated
by LiCl (Fig. 2c). However, DOT1L inhibition did not
induce detectable changes in active b-catenin levels in human
articular chondrocytes (Fig. 2b) or in the articular cartilage of
EPZ-5676-injected mice (Supplementary Fig. 4a). This suggests
that DOT1L regulates Wnt signalling downstream of b-catenin
stabilization. Effectively, messenger RNA levels of direct Wnt
target genes (LEF1, TCF1 and c-MYC)14–16 increased after
DOT1L inhibition in LiCl-treated chondrocytes (Fig. 2d).
Likewise, DOT1L knockdown using small interfering RNA
(siRNA) led to upregulation of these Wnt target genes in
LiCl-treated cells (Fig. 2e). In another set-up of Wnt signalling
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pathway activation using recombinant Wnt3a protein, DOT1L
inhibition also resulted in increased Wnt target gene expression
(Supplementary Fig. 5a). EPZ-5676 also augmented levels of these
Wnt targets in the dedifferentiation assay (Supplementary
Fig. 1c). In vivo, increased Wnt target gene expression was
demonstrated by immunohistochemistry of TCF1 in adult mouse
articular cartilage after DOT1L inhibition (Fig. 2f). Altogether,
these data suggest that DOT1L restrains active Wnt signalling in
cartilage.
To show that hyper-activation of Wnt signalling is the main
mechanism responsible for the pathological effects of DOT1L loss
of activity in articular cartilage, we assessed whether the Wnt
inhibitor XAV-939 counteracts the effects of EPZ-5676 in vitro
and in vivo. In healthy human articular chondrocytes, XAV-939
treatment rescued the loss of ACAN, COL2A1 and the increase of
COL1A1 triggered by DOT1L inhibition (Fig. 3a). Likewise,
in vivo, Wnt inhibition by XAV-939 also protected mice from
EPZ-5676-induced osteoarthritic changes (Fig. 3b,c). Thus,
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Figure 1 | Loss of DOT1L disrupts chondrocyte homeostasis and triggers osteoarthritis. (a) Immunohistochemistry showing reduced methylated H3K79
levels (H3K79me2) that reﬂect loss of DOT1L activity in damaged areas from osteoarthritic patients (OA) as compared to their corresponding preserved
areas and to cartilage from non-OA patients. Images are representative of images from four different patients. Scale bar, 400 mm. (b) Heat maps of
differential mRNA expression determined by quantitative PCR in chondrocytes treated with DOT1L inhibitor EPZ-5676 (EPZ) or vehicle (V) from passage
0 (P0) until P2, and from preserved versus damaged areas in OA cartilage. The colour code represents the mean expression level of six and four
independent patient samples respectively. (c) Immunoblot analysis showing decreased methylated H3K79 levels in mouse articular chondrocytes after
intra-articular injection of EPZ into C57Bl/6 wild-type mouse knees. The image is representative of one experiment with protein extracts pooled from two
or three mice per condition. Unprocessed original scans of blots are shown in Supplementary Fig. 10. (d,e) C57/Bl6 wild-type mouse knees were injected
with EPZ (5mg kg–1) or vehicle and killed after 2 or 4 weeks. Knees were sectioned and stained with Hematoxylin-Safranin O (d). Scale bar, 200mm.
Cartilage damage was scored (see Methods section) and is shown in (e). One experiment was performed with n¼ 10 and 5. Representative images from
the 4 week evaluation are shown. *Po0.05 (two-tailed t-test). Error bars indicate mean±s.e.m.
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hyper-activation of Wnt signalling is the major deleterious
downstream effect of loss of DOT1L activity in cartilage.
Chondrocytes are also found in the growth plate cartilage, a
transient tissue that becomes gradually replaced by bone during
skeletal development and growth. In developmental bone
formation and in the growth plate, active Wnt signalling has an
important role in terminal differentiation of these chondrocytes
towards hypertrophic cells. These cells express type X collagen
(COLX), upregulate matrix metalloproteinase-13 (MMP-13)
and produce a calciﬁed extracellular matrix. In osteoarthritis,
hyper-activation of Wnt signalling is associated with ectopic
hypertrophic differentiation11,17. Altered matrix composition and
factors secreted by these hypertrophic-like articular chondrocytes,
such as MMP-13, likely contribute to cartilage degeneration in
osteoarthritis17. We detected increased immunohistochemical
staining of COLX and MMP-13 in the articular cartilage of
EPZ-5676-injected mice, particularly in the vicinity of lesions
(Supplementary Fig. 4b,c). Thus, DOT1L also protects against
osteoarthritis by preventing Wnt-associated ectopic chondrocyte
hypertrophy in the articular cartilage.
DOT1L controls Wnt activity by negative regulation of SIRT1.
To investigate whether DOT1L directly regulates the Wnt
pathway at the transcriptional level, we studied the binding of
DOT1L to and its activity on different Wnt target genes in
human articular chondrocytes. Chromatin immunoprecipitation-
quantitative PCR (ChIP-qPCR) demonstrated that DOT1L and
methylated H3K79 bound to LEF1 and TCF1, but not to c-MYC
genes around the transcriptional start site (TSS) in response to
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Figure 2 | DOT1L negatively regulates Wnt signalling in articular cartilage. (a) KEGG pathway enrichment analysis of microarray data obtained from
human articular chondrocytes treated with EPZ-5676 or vehicle. Nominal P values by EASE modiﬁed Fisher Exact test using the DAVID analysis tool
(see Methods section) are shown. n¼ 5 independent patient-derived cell cultures. (b) Co-immunoprecipitation (Co-IP) using an anti-DOT1L antibody
showing interaction between DOT1L and b-catenin in human articular chondrocytes, that is increased upon Wnt activation by LiCl and disrupted upon
DOT1L inhibition. The image is representative of three experiments. (c) TOP/FOP reporter assay in human articular chondrocytes after Wnt stimulation by
LiCl and DOT1L inhibition by EPZ. Activity is compared to untreated cells (dotted line). n¼ 3 biologically independent experiments. ***Po0.001 by one-way
ANOVA. (d,e) LEF1, TCF1 and c-MYC expression measured by quantitative PCR in chondrocytes treated with EPZ-5676 and LiCl (d) or in LiCl-treated
chondrocytes transfected with siRNA directed against DOT1L or scrambled siRNA (siDOT1L or siSCR, respectively) (e). Data are from one experiment with
three technical replicates. (f) Immunohistochemistry demonstrating increased TCF1 levels in the articular cartilage of C57/Bl6 wild-type mice after
injection of EPZ-5676. The images are representative of three different animals. Scale bar, 200mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15889
4 NATURE COMMUNICATIONS | 8:15889 |DOI: 10.1038/ncomms15889 | www.nature.com/naturecommunications
Wnt pathway activation with either LiCl or Wnt3a (Fig. 4a and
Supplementary Fig. 5b). The binding strongly decreased upon
EPZ-5676 treatment or siRNA-mediated DOT1L knockdown
(Fig. 4a and Supplementary Fig. 5b). Loss of H3K79 methylation
was accompanied by higher levels of acetylated H3K9 and
trimethylated H3K4, histone marks associated with active
transcription, at the LEF1 and TCF1, but not c-MYC promoters
(Fig. 4b). Thus, DOT1L acts as a direct negative regulator of Wnt
target genes in chondrocytes.
We next sought to elucidate the molecular mechanism by
which DOT1L negatively regulates Wnt signalling in cartilage.
We hypothesized that DOT1L interacts with a repressor to
restrict Wnt target gene expression. To test our hypothesis, we
assessed whether knockdown of potential repressor candidates
mimicked the effects of DOT1L inhibition in LiCl-treated human
articular chondrocytes. As candidates, we evaluated AF4, AF5
and AF10, which are known DOT1L binding partners in
leukaemia18–20 with reported roles in gene repression21,22 or as
enhancers of DOT1L effects23. We also considered as candidates
BCOR, SIRT1 and CBX8, proteins earlier identiﬁed in DOT1L
complexes by mass spectrometry, with a known role as
transcriptional repressors24. Silencing of any of these candidates
did not upregulate LEF1 or TCF1 expression in Wnt-activated
cells (Fig. 4c and Supplementary Fig. 6a). Therefore, we did not
further consider their possible role as transcriptional repressors in
interaction with DOT1L.
Surprisingly, in DOT1L-inhibited cells, we found that silencing
of SIRT1 blocked the upregulation of LEF1, TCF1 but not c-MYC
observed after DOT1L inhibition (Fig. 4c and Supplementary
Fig. 6a). Likewise, the SIRT1 speciﬁc inhibitor EX527 rescued the
upregulation of LEF1 and TCF1 triggered by DOT1L inhibition in
LiCl-treated cells (Fig. 4d and Supplementary Fig. 6b).
In contrast, pharmacological activation of SIRT1 with SRT1720
in LiCl/EPZ-5676-treated cells further upregulated LEF1, TCF1
but not c-MYC (Fig. 4d and Supplementary Fig. 6b). These
unexpected results prompted us to consider that SIRT1 drives
Wnt hyper-activation upon DOT1L blockade in chondrocytes.
We next investigated the mechanism by which SIRT1 increases
Wnt target gene expression upon DOT1L inhibition.
Immunoprecipitation demonstrated that DOT1L and SIRT1
interacted at the protein level in human articular chondrocytes
and this interaction was disrupted by DOT1L inhibition (Fig. 4e).
Notably, we found that DOT1L inhibition increased the
enzymatic activity of SIRT1 (Fig. 4f). DOT1L knockdown using
siRNA likewise resulted in enhanced SIRT1 activity (Fig. 4f).
However, since ChIP-qPCR showed no SIRT1 protein occupancy
at the DOT1L-identiﬁed Wnt target genes upon DOT1L
inhibition in our experimental conditions (Fig. 4g and
Supplementary Fig. 6c), we hypothesized that SIRT1’s effects
may be accomplished by downstream chromatin binding factors.
We therefore focused on PPARGC1A, GCN5 and EP300,
transcriptional activators linked to the SIRT1 network25.
Silencing of these factors mimicked SIRT1 silencing and
partially blocked LEF1 and TCF1 but not c-MYC upregulation
by EPZ-5676 in LiCl-treated chondrocytes (Fig. 4h and
Supplementary Fig. 6d). ChIP-qPCR demonstrated strong
enrichment for PPARGC1A and to a lesser extent for GCN5 at
the LEF1 and TCF1 promoters after EPZ-5676 treatment (Fig. 4g
and Supplementary Fig. 6c). Furthermore, the SIRT1 inhibitor
EX527 that rescued EPZ-5676 effects on Wnt targets (Fig. 4d and
Supplementary Fig. 6b), reduced the occupancy of PPARGC1A
and GCN5 at LEF1 and TCF1 promoters (Fig. 4g and
Supplementary Fig. 6c). Thus, these results indicate that
increased SIRT1 activity upon DOT1L inactivation induces
chromatin binding of transcriptional activators and promotes
the upregulation of Wnt target genes.
SIRT1 blockade prevents EPZ-5676-induced osteoarthritis.
We then examined the therapeutic implications of our ﬁndings,
and explored the therapeutic potential of blocking SIRT1 in
preventing osteoarthritis triggered by DOT1L inactivation. We
therefore intra-articularly co-injected the SIRT1 inhibitor EX527
and the DOT1L inhibitor EPZ-5676. Pharmacological blockade of
SIRT1 effectively reduced the severity of osteoarthritis caused
by the DOT1L inhibitor (Fig. 5a,b), and reversed the
hyper-activation of Wnt signalling (Fig. 5c). Thus, we discovered
that modulation of SIRT1 activity is a leading mechanism by
which DOT1L controls activation of Wnt signalling, maintains
cartilage health and prevents osteoarthritis.
Loss of DOT1L causes severe growth retardation in mice.
The DOT1L inhibitor EPZ-5676 is currently under clinical
investigation as a potential treatment for MLL-rearranged
leukaemia in adults and children26,27. Our loss of function data in
the articular cartilage resulting in osteoarthritis suggest that
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speciﬁc attention should be given to cartilage in patients treated
with DOT1L inhibitors. Of note, polymorphisms in the DOT1L
gene are not only associated with osteoarthritis but also with
height28. To assess whether loss of DOT1L has also an impact on
growth plate chondrocytes and may inﬂuence growth in children
treated with DOT1L inhibitors, we bred ﬂoxed Dot1l mice
(Dot1lﬂ/ﬂ) with a Col2-cre deleter mouse strain to obtain speciﬁc
recombination in chondrocytes (Supplementary Fig. 7).
Cartilage-speciﬁc Dot1l knockout mice (Dot1lCart-KO mice) did
not show apparent skeletal abnormalities but displayed severe
growth retardation (Fig. 5d). Histology of the growth plates
demonstrated a reduced and disorganized proliferative and
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Figure 4 | DOT1L directly controls Wnt targets by negative regulation of SIRT1. All experiments were performed in healthy human articular
chondrocytes: treated as indicated with DOT1L inhibitor EPZ-5676, Wnt activator LiCl, SIRT1 antagonist EX527 or SIRT1 agonist SRT1720; or transfected
with DOT1L or scrambled siRNA. All data are presented as mean±s.e.m. (a) Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) analysis of
DOT1L and methylated H3K79 and (b) acetylated H3K9 (H3K9Ac) and methylated H3K4 (H3K4me3) as markers of active transcription on the
transcriptional start site (TSS) of Wnt target genes. Data are from two to ﬁve experiments. (c) Expression levels of TCF1 Wnt target gene measured by
quantitative PCR in chondrocytes transfected with indicated speciﬁc or scrambled siRNA (siSCR). Data are from one experiment with technical triplicates.
(d) TCF1 expression measured by quantitative PCR in the presence of SIRT1 agonist and antagonist. Data from two experiments each with technical
triplicates. (e) Co-IP analysis using the indicated antibodies demonstrating the interaction of DOT1L and SIRT1. The image is a representative image of three
biologically independent experiments. (f) SIRT1 activity relative to vehicle-treated cells (dotted line). Data are from three biologically independent
experiments. *Po0.05, ***Po0.001 by one-way ANOVA. (g) ChIP-qPCR analysis of SIRT1, PPARGC1A, GCN5 and EP300 binding on the TCF1 promoter
and (h) TCF1 expression after siRNA transfection with indicated speciﬁc or scrambled siRNA. Data from two biologically independent experiments.
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prehypertrophic zone (Fig. 5e). Increased Wnt pathway activation
in the absence of DOT1L was demonstrated by
immunohistochemistry of TCF1 in the articular cartilage and
growth plate of Dot1lCart-KO mice (Fig. 5f,g), with no detectable
changes in b-catenin activation (Supplementary Fig. 8a,b). The
pattern and the intensity of the immunoreactive signal for COLX
was different in the growth plate of Dot1lCart-KO mice compared
to controls (Supplementary Fig. 8d). Of note, COLX levels also
appeared to be increased in the articular cartilage of Dot1lCart-KO
mice (Supplementary Fig. 8c). Similarly, MMP-13 levels appeared
to be increased in the articular cartilage of Dot1lCart-KO mice
(Supplementary Fig. 8e) but not in the growth plate
(Supplementary Fig. 8f). Hence, these in vivo data demonstrate
that DOT1L not only regulates cartilage homeostasis but also
skeletal growth, and caution against undesired growth effects
when DOT1L inhibitors are used in children.
Discussion
In this study, we show that DOT1L safeguards the homeostasis of
the articular cartilage and protects against osteoarthritis. We
propose a new signalling model in cartilage (Fig. 6) linking Wnt
activation with recruitment of DOT1L multi-protein complexes
to Wnt target genes such as TCF1 and LEF1. Under normal
conditions, DOT1L prevents Wnt hyper-activation by negative
modulation of SIRT1, thereby maintaining cartilage homeostasis.
Upon DOT1L loss of function, DOT1L complexes disassemble,
SIRT1 activity increases and transcriptional activators are
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recruited in a SIRT1-dependent manner. Wnt target gene
expression strongly increases, and triggers loss of cartilage
homeostasis, in vivo resulting in osteoarthritis. Interestingly, in
the joint, the effects of DOT1L on Wnt signalling appear to be
cell-speciﬁc for chondrocytes as these were absent in osteoblasts
(Supplementary Fig. 9).
In genome-wide association studies, polymorphisms in
the DOT1L gene were linked with cartilage thickness and
osteoarthritis6,29,30, as well as with height28. We earlier
demonstrated that silencing of Dot1l in mouse
chondroprogenitor cells negatively inﬂuences chondrogenic
differentiation and that DOT1L interacts with Wnt pathway
transcription factor TCF4 in these cells6. An interaction between
Wnt signalling molecule b-catenin and DOT1L was further
demonstrated in human cell lines18,31, in mouse intestinal
crypts18, in colorectal cancer18, in drosophila31 and in
zebraﬁsh18. Remarkably, and in sharp contrast with our
observations in the articular chondrocytes, DOT1L and H3K79
methylation have been mostly linked to increased Wnt target
gene expression6,18,31. Our observation that DOT1L prevents the
deleterious hyper-activation of Wnt signalling in articular
chondrocytes highlights that the regulatory effects of DOT1L
on gene expression are strongly tissue and context dependent32,
thereby opening opportunities for highly speciﬁc interventions.
A ﬁne-tuned balance of Wnt activity is considered
indispensable for cartilage and joint homeostasis13. Both
excessive activation and lack of Wnt signalling in the joint
result in cartilage breakdown and osteoarthritis in animal
models11,33. Our new paradigm proposes that DOT1L can act
as a brake to contain the hyper-activation of the Wnt signalling
cascade but does not fully inhibit its physiological role. A similar
function has recently been described for WNT16. Nalesso et al.34
suggest that WNT16 prevents excessive Wnt activation in
articular cartilage by acting as a partial agonist of this cascade,
thereby competing for receptor binding with a full agonist. We
also earlier demonstrated that lack of extracellular Wnt
antagonist frizzled-related protein increases the severity of
osteoarthritis in mouse models12. Thus, our novel data on
DOT1L as a critical modulator of the Wnt cascade add another
level of complexity to the regulation of Wnt signalling in the
articular cartilage: in addition to extracellular agonists and
antagonists, the Wnt cascade is also tightly controlled at the
chromatin level. The cell-speciﬁcity of our ﬁndings suggests that
this epigenetic mechanism may be a more precise therapeutic
target as compared to extracellular modulators.
The factors that regulate DOT1L activity in the articular
cartilage remain unknown and are an important area for further
research. We did not detect differences in DOT1L gene expression
levels between damaged or preserved cartilage from patients with
osteoarthritis. However, this does not exclude transcriptional
control as a mechanism to regulate DOT1L activity.
In osteoarthritis, articular chondrocytes are not a uniform
population and their health status may determine the expression
of DOT1L at the individual cell level. Interestingly, some evidence
suggests that pro-inﬂammatory signals activating NFkB signalling
increase DOT1L expression35. This may be a compensatory
mechanism to promote DOT1L activity and has been linked to
ageing. Nevertheless, our data in the patient cartilage samples
suggest that regulation of DOT1L activity is the main mechanism
to control H3K79 methylation and its effects on gene
transcription. The intrinsic catalytic activity of DOT1L is
considered relatively low and the limited number of DOT1L
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molecules in the cells does not match the high number of
histones36. Thus, DOT1L should be directed to and activated at
particular stretches of the DNA36. For instance, trans-histone
cross-talk with ubiquitination at H2B not only interacts with
DOT1L but contributes to the positioning of the enzyme to
optimize H3K79 methylation37. Cumulative data suggest that
there is no speciﬁc demethylase for H3K79 (ref. 36). Thus,
demethylation of H3K79 appears to be largely due to histone
renewal and cell division.
Our results identify a critical interaction between DOT1L and
SIRT1 in articular chondrocytes. SIRT1 is a deacetylase with
effects on epigenetic regulation of gene expression as well as other
molecules, thus inﬂuencing different pathways38. We detected
protein–protein interactions between DOT1L and SIRT1 in the
transcriptional complex assembling upon activation of
Wnt signalling. Within these complexes, DOT1L negatively
regulates SIRT1 activity. Again, the downstream effects of
the DOT1L-SIRT1 interaction appear to be strongly
context-dependent. Whereas in chondrocytes inhibition of
DOT1L results in increased Wnt signalling dependent on
SIRT1, in DOT1L mediated mixed-lineage leukaemia, SIRT1 is
part of an antitumoral repressive complex39. In the collecting
ducts in the kidney, DOT1L and SIRT1 interact to suppress
the expression of the epithelial Na(þ ) channel a-subunit
(alpha-ENaC). Inhibition of SIRT1 resulted in higher levels of
alpha-ENaC40.
The deleterious effects of SIRT1 reported in this study may
appear to be in contrast with its perceived role in cartilage biology
and osteoarthritis41. Studies in genetic models have indicated that
lack of SIRT1 activity in cartilage results in delayed growth and
spontaneous osteoarthritis42,43, as well as increases the severity of
osteoarthritis in the destabilization of the medial meniscus
model44. SIRT1 activator resveratrol protects against
osteoarthritis in the same model45. However, in vitro, this drug
triggers chondrocyte hypertrophy46. This apparent discrepancy
with our observations can be explained by the broad biological
effects of SIRT1, including control of metabolism and
mitochondrial activity. The deacetylase activity of SIRT1 is not
limited to histone modiﬁcations but also affects other molecules
in the cell, including transcription factors such as forkhead
proteins47. In addition, in the absence of SIRT1, DOT1L activity
and the composition of these multi-protein complexes may be
altered, thereby potentially affecting its protective role in cartilage.
The severe growth retardation in Dot1lCart-KO mice remains
intriguing. Further analysis suggests that the absence of Dot1l in
chondrocytes disrupts the architecture of the growth plate with
increased expression of COLX and MMP-13, markers of
hypertrophic differentiation. Taking into account that we did
not observe a role for DOT1L as a key regulator of Wnt signalling
in primary osteoblasts, novel insights into the role of DOT1L in
development and growth may result from experiments with other
Cre-drivers such as Prx1. Obviously, speciﬁc attention should be
given to growth retardation in children affected by leukaemia that
are being treated with DOT1L inhibitors.
Further research will also be required to translationally validate
the DOT1L/SIRT1 balance as a therapeutic target. Our different
rescue and silencing experiments suggest speciﬁcity of the
observed effects in vivo and in vitro. The severe growth phenotype
in Dot1lCart-KO mice precludes their use in induced or ageing
models of osteoarthritis. Inducible conditional models, for
instance using a tamoxifen or doxicyclin dependent collagen
type II or aggrecan Cre-driver, may overcome these issues,
although leakiness or postnatal activity loss of the Cre transgenes
can be a limitation48. Nevertheless, such approaches will
be necessary to further understand the role of DOT1L in
joint disease, and more in particular in post-traumatic or
ageing-associated osteoarthritis. Moreover, the association
between polymorphisms in DOT1L and osteoarthritis has been
most strongly demonstrated for hip osteoarthritis6. Inducible
tissue-speciﬁc genetic models may be useful to understand
eventual differences between hip and knee disease.
In summary, our study provides novel information on DOT1L
in mammalian gene regulation and identiﬁes DOT1L as a key
regulator of transcriptional programs essential for cartilage
health. The balance between DOT1L and SIRT1 activity
determines the activation of Wnt signalling in cartilage, with
excessive pathway activity resulting in osteoarthritis. New
epigenetics-based strategies, in particular those targeting
the DOT1L network, could provide an innovative way for
therapeutic modulation of Wnt signalling in joint disease and the
development of effective treatments of osteoarthritis.
Methods
Materials. The speciﬁc DOT1L inhibitor EPZ-5676 was obtained from Chemietek.
Lithium chloride and EX527 were purchased from Sigma, XAV-939 from Selleck
and SRT1720 from Calbiochem. HiPerFect and all siRNAs except DOT1L siRNA
were purchased from Qiagen (Supplementary Table 2). DOT1L siRNA and
lipofectamine RNAimax were purchased from Invitrogen. Recombinant human
WNT3A protein was purchased from R&D Systems.
Mice. All experiments with mice were approved by the Ethics Committee for
Animal Research (KU Leuven, Belgium). Wild-type male C57Bl/6 mice were
purchased from Janvier (Le Genest St Isle, France). Dot1l transgenic mice (Dot1lTg)
were obtained from the Knockout Mouse Project (KOMP) (CSD29070) (ref. 49).
Heterozygous mice were crossed to Gt(ROSA)26Sortm1(FLP1)Dym mice (Jax 003946)
for the removal of the Stop-cassette, to obtain Dot1l mice in which exon 2 is
ﬂanked by loxP sites (Dot1lﬂ). These mice were further bred to Tg
(Col2a1.Cre)o1Bhr4 mice (Jax 003554) to generate conditional cartilage-speciﬁc
Dot1l knockout mice (Dot1lﬂ/ﬂ; Col2-Creþ / or Dot1lCart-KO). Genotypes of
animals were conﬁrmed by PCR on genomic ear DNA.
EPZ-5676, XAV-939 and EX527 intra-articular injections. The concentration
range for the in vivo administration of DOT1L inhibitor EPZ-5676 was estimated
based on reported pharmacokinetics data in mouse50. From the range that we
tested in a pilot study, we selected the minimum effective concentration that
showed to inhibit DOT1L methylation (5mg kg–1). DOT1L inhibitor EPZ-5676,
Wnt inhibitor XAV-939 (0.1 and 0.5mg kg–1) (ref. 51), SIRT1 inhibitor EX527
(1.25mg kg–1) (ref. 52) or vehicle was injected intra-articularly in the right knee of
male 8-week-old wild-type C57Bl/6 mice four times, with an interval of 4 days. PBS
was injected in the left knee.
Histology. Wild-type C57Bl/6 mice injected with EPZ-5676, XAV-939, EX527 or
vehicle were killed 2 or 4 weeks after the ﬁrst injection. Right and left knees from
these mice were ﬁxed overnight at 4 C in 2% formaldehyde, decalciﬁed for 3
weeks in 0.5M EDTA pH 7.5, and embedded in parafﬁn. Dot1lﬂ/ﬂ; Col2-Cre /
(Cre-neg) and Dot1lCart-KO male and female littermate mice were killed at the age of
4 weeks and right knees were ﬁxed overnight at 4 C in 2% formaldehyde,
decalciﬁed for 2 weeks in 0.5M EDTA pH 7.5 and embedded in parafﬁn.
Hematoxylin-Safranin O staining and immunohistochemistry were performed on
5 mm thick sections. Severity of disease was determined by histological scores on
Hematoxylin-Safranin O stained sections throughout the knee by a blinded
investigator (ﬁve sections at 100 mm distance). Both cartilage damage and synovial
hyperplasia were assessed based on OARSI guidelines53. Depth of lesion (0–6) was
scored on frontal knee sections. Lesion grades represent the following features;
0: surface and cartilage morphology intact, 1: small ﬁbrillations without loss of
cartilage, 2: vertical clefts below superﬁcial layer and some loss of surface lamina,
3-6: vertical clefts/erosions to the calciﬁed cartilage extending, 3: less than 25%,
4: 25–50%, 5: 50–75% and 6: more than 75%. The score represents the mean of the
tibial scores at the medial and lateral side. For synovial hyperplasia, severity was
determined on a 0–3 scale. Scoring was done by two independent readers, blinded
to the genotype.
Subchondral bone plate histomorphometry. Histomorphometry was performed
on Safranin O stained sections using an Olympus IX83 microscope and digital
image analysis using Osteomeasure software, as previously described54. First, a box
with a ﬁxed width (800 mm) and variable height with the upper limit at the
transition of calciﬁed cartilage to subchondral bone and the lower limit at the
transition submchondral bone to growth plate was created from the digital image
(referred to as subchondral bone area). Next, a new box with the upper limit
matched to the ﬁrst box and the lower limit at the transition of the subchondral
bone plate to trabecular bone was generated (referred to as subchondral bone plate
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15889 ARTICLE
NATURE COMMUNICATIONS | 8:15889 |DOI: 10.1038/ncomms15889 | www.nature.com/naturecommunications 9
area). Subchondral bone area and subchondral bone plate area were calculated
using the Osteomeasure software. To correct for section artifacts, we do not show
the subchondral bone plate surface area per se, but express the subchondral bone
plate thickness as a ratio of the subchondral bone plate area to the subchondral
bone area.
Immunohistochemistry. Immunohistochemistry was performed on parafﬁn
embedded EDTA decalciﬁed mouse knee sections and on parafﬁn embedded
sections of human cartilage explants from osteoarthritic patients and control
trauma patients. Heat-induced epitope retrieval was performed using a
Citrate-EDTA buffer (pH 6.2) for 10min at 98 C. Next, sections were treated with
3% H2O2/methanol for 10min to inactivate endogenous peroxidase activity. Then,
sections were blocked in normal goat serum for 30min and incubated overnight at
4 C with the primary antibodies against COLX (Abcam, ab58632; dilution 1:250
in EPZ-5676-injected mice and 1:400 in cartilage-speciﬁc Dot1l knockout mice),
b-catenin (Abcam, ab6302; dilution 1:750), MMP-13 (Abcam, ab39012; dilution
1:100 in EPZ-5676-injected mice and 1:175 in cartilage-speciﬁc Dot1l knockout
mice), TCF1 (Abcam, ab96777; dilution 1:100) or H3K79me2 (Abcam, ab3594;
dilution 1:100). Rabbit IgG (Santa Cruz, sc-2027) was used as a negative control. In
addition, the ABC-ampliﬁcation technique (avidin-biotin complex) (Vectastain
ABC kit, Vector Laboratories, USA) was used, except for the immunohistochemical
detection of H3K79me2. Finally, peroxidase goat anti-rabbit IgG (Jackson
Immunoresearch, Suffolk, UK) was applied for 30min and peroxidase activity
was determined using DAB. For the detection of COLX, antigen retrieval was
performed enzymatically with 10mgml–1 Hyaluronidase (Sigma-Aldrich, H3884)
in MgCl2- free PBS, for 40min at 37 C. In this case, endogenous peroxidase
activity was blocked after the incubation with the primary antibody.
Skeletal staining. Cre-neg and Dot1lCart-KO male and female littermate mice were
killed at the age of 4 weeks, eviscerated and ﬁxed for 5 days at room temperature in
95% ethanol. After dissolving the fat in acetone for 1 day, cartilage was stained with
Alcian Blue (8GX, Sigma-Aldrich; 20% glacial acetic acid, 80% ethanol and
150mg l–1 Alcian Blue) for 1.5 days. Skeletons were rinsed twice with 95% ethanol
for 2 days, before being cleared in 1% KOH for 1 day. Mineralized tissue, including
bone, was then stained with Alizarin Red (Sigma-Aldrich; 50mg l–1 in 2% KOH)
for 1.5 days. Afterwards, skeletons were cleared in 2% KOH for 6–8 days and then
moved to a solution of 2% KOH and glycerol (80:20, respectively) for 4 days.
Finally, skeletons were passed every 24 h to a solution of 2% KOH and glycerol
with subsequent decreasing ratios of 2% KOH (60:40, 40:60 and 20:80,
respectively).
Cell culture. Human articular chondrocytes were isolated from the hips of patients
undergoing total hip replacement surgery. The University Hospitals Leuven Ethics
Committee and Biobank Committee approved the study and specimens were taken
with patients’ written consent. Healthy articular chondrocytes were obtained from
patients undergoing hip replacement for osteoporotic or malignancy-associated
fractures. In specimens from osteoarthritic patients, obtained during prosthesis
surgery, cartilage tissue was ﬁrst classiﬁed macroscopically as either intact or
damaged as described previously55 taking into account colour, surface integrity and
tactile impression tested with a scalpel. Cartilage was dissected from the joint
explant surfaces and then rinsed with saline. The tissue was cut into small pieces,
using a sterile surgical blade. Cartilage explants were incubated with 2mgml–1
pronase solution (Roche) for 90min at 37 C and digested overnight at 37 C in
1.5mgml–1 collagenase B solution (Roche) under continuous agitation. The
preparation was ﬁltered through a 70 mM strainer and cells were plated in culture
ﬂasks and cultured in a humidiﬁed atmosphere at 37 C, 5% CO2. After reaching
conﬂuency, cells were passaged 1:3. Culture medium consisted of DMEM/F12
(Gibco), 10% fetal bovine serum (FBS) (Gibco), 1% (vol/vol) antibiotic/antimycotic
(Gibco) and 1% L-glutamine (Gibco).
Primary human osteoblasts were isolated from the hips of patients undergoing
total hip replacement surgery, using a modiﬁcation of Beresford’s procedure56.
Trabecular bone was removed mechanically from the femur head, washed several
times with sterile PBS to remove adherent cells and cut into 2–4mm2 pieces. These
explants were agitated in culture medium (1:1 mixture of DMEM and Ham’s F12
medium (Gibco) containing 1% (vol/vol) antibiotic-antimycotic (Gibco), 10% FBS
(Gibco) and 1% L-glutamine (Gibco)), placed in a culture ﬂask and incubated at
37 C in a humidiﬁed atmosphere of 95% air and 5% CO2. To favour osteoblastic
differentiation, the standard culture medium was supplemented with 100 mgml–1
ascorbic acid (Sigma) and 10mM b-glycerophosphate (Sigma). Non-adherent
cells were removed after 3 days and afterwards the culture medium was changed
twice a week. Primary cultures were maintained for 10–15 days until conﬂuency
(passage 0) when adherent cells were enzymatically released with 0.04%
trypsin-EDTA solution. The resultant cell suspension was subcultured with
standard cultured medium.
For the in vitro studies, cells were treated with 3 mM EPZ-5676, 20mM LiCl,
1 mM XAV-939, 1 mM SRT1720 and/or 10mM EX527, unless otherwise indicated.
Small interfering RNA transfection was performed with 50 nM siRNA and
HiPerFect or lipofectamine RNAimax (for DOT1L siRNA) for 48 h according to
the manufacturer’s instructions.
Chondrocyte dedifferentiation assay. Freshly isolated healthy human articular
chondrocytes were seeded in monolayer and expanded from passage 0 up to
passage 5. The cells were treated with 3 mM EPZ-5676 or vehicle every 3–4 days,
during the cell expansion and associated dedifferentiation process. Protein and
RNA were isolated at each passage when cells reached conﬂuency. Effective DOT1L
inhibition by EPZ-5676 at each passage was conﬁrmed by Western blot analysis of
H3K79 methylation. For the readout of the experiment, genes of interest were
selected from a chondrocyte dedifferentiation transcriptome analysis taking into
account the gene’s known role in chondrocyte biology. The gene expression of
those selected genes was measured by qPCR.
Cell lysis and western blotting. Cells were homogenized in IP Lysis/Wash buffer
(Thermo Fisher) supplemented with 5% (vol/vol) Protease Mixture Inhibitor
(Sigma) and 1mM phenylmethanesulfonyl (Sigma). After two homogenization
cycles (7 s) with an ultrasonic cell disruptor (Microson; Misonix), total cell lysates
were centrifuged 10min at 18,000g, and supernatant containing proteins was
collected. The protein concentration of the extracts was determined by Pierce BCA
Protein Assay Kit (Thermo Scientiﬁc). Immunoblotting analyses were performed as
described in previous studies3. Antibodies against Actin (Sigma, A2066; dilution
1:4,000), active b-catenin (Merck Millipore, 05-665, clone 8E7; dilution 1:1,000),
total b-catenin (BD biosciences, 610154, clone 14/b-catenin; dilution 1:2,000),
DOT1L (Bethyl, A300-954A; dilution 1:1,000), GAPDH (Ambion, AM4300, clone
6C5; dilution 1:10,000), total H3 (Abcam, ab1791; dilution 1:10,000), H3K79me2
(Abcam, ab3594; dilution 1:1,000), and SIRT1 (Cell signalling, 2496, clone C14H4;
dilution 1:1,000) were used following manufacturer’s instructions. The blotting
signals were detected using the SuperSignalWest Femto Maximum Sensitivity
Substrate system (Thermo Scientiﬁc).
Quantitative PCR. Total RNA was extracted using the Nucleospin RNA II kit
(Macherey-Nagel). cDNA was synthesized using 500 ng RNA isolated from human
articular chondrocytes with the RevertAidHminus First Strand cDNA synthesis kit
(Fermentas) according to the manufacturers’ recommendations. Quantitative PCR
analyses were performed as described previously using Maxima SYBRgreen qPCR
master mix system (Fermentas)6. Gene expressions were calculated following
normalization to housekeeping gene S29 mRNA levels using the comparative Ct
(cycle threshold) method. The following PCR conditions were used: incubation for
10min at 95 C followed by 40 ampliﬁcation cycles of 15 s of denaturation at 95 C
followed by 45 s of annealing-elongation at 60 C. Melting curve analysis and 1%
agarose gel migration of amplicons were performed to determine the speciﬁcity of
the PCR. Primers used for qPCR analysis are listed in Supplementary Table 3.
Microarray hybridization and data acquisition. For the microarray, human
articular chondrocytes were obtained from ﬁve non-OA hip fracture patients.
The cells were treated with 3 mM EPZ-5676 or vehicle control for 4 days. Each
sample was divided in two: one half was used for protein extraction and the other
half for RNA extraction. Effective DOT1L inhibition by EPZ-5676 was conﬁrmed
by Western blot analysis of H3K79 methylation. RNA was isolated with Nucleospin
RNA II kit (Macherey-Nagel). RNA concentration and purity were assessed with a
NanoDrop Spectrophotometer (NanoDrop Technologies, Centreville, DE, USA)
and integrity was determined using RNA nanochips and the Agilent 2100
Bio-analyzer (Agilent Technologies, Diegem, Belgium). Only non-degraded RNA
without impurities (RNA integrity number47.7), was considered for microarray
analysis. Transcriptional proﬁles were analysed by the VIB Microarray Facility
(Nucleomics Core. Microarrays, nCounter, next-gen sequencing and
bioinformatics. http://www.microarray.be). Per sample, 2 mg of total RNA spiked
with bacterial RNA transcript positive controls (Affymetrix, Santa Clara, CA, USA)
was converted to double stranded cDNA. Subsequently, the sample was converted
and ampliﬁed to antisense cRNA and labelled with biotin. A mixture of puriﬁed
and fragmented biotinylated cRNA and hybridization controls (Affymetrix) was
hybridized on Affymetrix Human U133 Plus 2.0 arrays followed by staining and
washing in a GeneChip ﬂuidics station 450 (Affymetrix). To assess the raw probe
signal intensities, chips were scanned using a GeneChip scanner 3000 (Affymetrix).
The differentially expressed genes were explored with the limma package. Genes
with nominal P values o0.05 were selected for the enrichment analysis. DAVID
version 6.7 (http://david.abcc.ncifcrf.gov/)57 or Toppgenesuite (https://
toppgene.cchmc.org)58 tools were used for gene network analyses including
categories KEGG pathway, GO molecular function, GO biological process, human
and mouse phenotypes. A minimum gene count of 12 representing 1% of the
differentially regulated genes recognized by DAVID was applied in the analysis.
PANTHER database version 11.1 (http://pantherdb.org)59 was used for graphical
representation of functional categories using the ‘PANTHER GO-slim’ and Protein
Class ontology resources.
Luciferase assay. Primary human chondrocytes were treated with vehicle or 3 mM
EPZ-5676 for 14 days. On day 15, cells were plated into 24-well plates and they
were transfected when they were 60–70% conﬂuent with mGFP control plasmid
(Origene PS100040) and Super8X TOPFlash or Super8X FOPFlash (TOPFlash
mutant control) (Addgene plasmids #12456 and #12457, respectively) for canonical
Wnt signalling reporter using Lipofectamine LTX Reagent with PLUS Reagent
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(Life Technologies) according to the manufacturer’s protocol. After 24 h, cells were
treated with 20mM LiCl with or without 3 mM EPZ-5676 and collected 24 h later.
Luciferase assay was performed using Promega Luciferase Assay system according
to the manufacturer’s protocol. Brieﬂy, cells were lysed with 400 ml per well 1
lysis buffer (E1531) and underwent two freeze-thaw cycles to ensure complete cell
lysis. Afterwards, 20ml of cell lysate was transferred to opaque 96-well plates, and
50ml of Luciferase Assay Reagent was dispensed into the plate. Luciferase level was
measured using Plate-Reading Luminoskan Ascent (Thermo Scientiﬁc).
ChIP analysis. Chromatin immunoprecipitation assays were carried out using the
Agarose ChIP kit from Thermo Scientiﬁc, according to the manufacturer’s
guidelines. Brieﬂy, cell samples were crosslinked by 1% formaldehyde for 10min,
and the reaction was stopped by the addition of glycine to a 125mM ﬁnal
concentration. The ﬁxed cells were lysed in SDS buffer, and the chromatin was
fragmented by microccocal nuclease digestion. The sheared chromatin was
incubated with antibodies against DOT1L (Bethyl, A300-954A; dilution 1:50),
GCN5 (Santa Cruz, sc-20698; dilution 1:20), H3K4me3 (Abcam, ab8580; dilution
1:100), H3K9ac (Abcam, Ab4441; dilution 1:125), H3K79me2 (Abcam, Ab3594;
dilution 1:100), EP300 (Abcam, ab14984, clone 3G230/NM-11), PPARGC1A
(Santa Cruz, sc-13067; dilution 1:20), SIRT1 (Abcam, Ab12193; dilution 1:100) and
recovered by binding to protein A/G agarose. Eluted DNA fragments were used
directly for qPCR. Primers used for ChIP-qPCR analysis are listed in
Supplementary Table 4.
Co-Immunoprecipitation. Co-Immunoprecipitation experiments were performed
using the Pierce Co-Immunoprecipitation Kit (Thermo Scientiﬁc). Columns
were conditioned following the manufacturer’s recommendations. Antibody
binding to the column was performed using 75 mg of either a mock antibody
(donkey anti-goat IgG) as a control or DOT1L antibody (R&D Systems, MAB6546,
clone 653613). After antibody immobilization, the columns were washed, and
100mg of the lysate’s proteins were incubated overnight at 4 C under constant
mixing. After four washings, retained proteins were eluted using 40 ml of Elution
Buffer (Thermo Fisher) pH 3, and stored at  80 C. Protein complexes were then
detected by Western blotting.
SIRT1 activity assay. The deacetylase activity of SIRT1 was determined by using
a SIRT1 Activity Assay Kit (Abcam, ab156065) as recommended by the
manufacturer. Brieﬂy, cells were washed with cold PBS, lysed in IP Lysis/Wash
buffer (Thermo Fisher) and incubated on ice for 5min. After two homogenization
cycles (7 s) with an ultrasonic cell disruptor (Microson; Misonix), total cell lysates
were centrifuged 10min at 13,000g, and supernatant containing proteins was
collected. The protein concentration of the extracts was determined by Pierce BCA
Protein Assay Kit (Thermo Scientiﬁc). Cell lysates (200 mg) were incubated with
anti-SIRT1 antibody (10 mg) (Abcam, ab7343) for 3 h at 4 C and then with protein
A Agarose beads for the next 1.5 h. Precipitates were incubated with Fluoro-Sub-
strate Peptide Solution, NADþ and SIRT1 Assay Buffer. Fluorescence intensity
was then measured using a microtitre plate ﬂuorometer with excitation at 360 nm
and emission at 460 nm.
Statistical analysis. Data are presented as mean and s.e.m. where indicated. No
statistical method was used to predetermine sample size for the animal experiments
as the initial intervention (EPZ-5676 treatment) was compared against a condition
expected to be close to normal. Additional interventions served as recue for the
EPZ-5676 effects. The experiments were not randomized. Statistical analyses were
performed where appropriate with GraphPad Prism software. For two group
analyses, Student’s t-test was used. For group analysis, one-way ANOVA with
post hoc tests taking into account multiple comparisons were used. For repeated
measurements two-way ANOVA was used analysing the effect of time,
intervention and the interaction between time and intervention. If the interaction
P value was smaller than 0.05, post hoc tests were performed as above as
appropriate. All tests were two-tailed.
Data availability. Microarray data that support the ﬁndings of this study have
been deposited in Gene Expression Omnibus with the primary accession code
GSE77916. The authors declare that all other data supporting the ﬁndings of this
study are available within the article and its supplementary ﬁles, or available from
the authors upon request.
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